Mode
Text Size
Log in / Sign up
N/A Completed N=3,719

Post Marketing Surveillance Study To Observe Safety And Efficacy Of Champix® Tablets

Source: ClinicalTrials.gov NCT00483002 ↗
Enrolled (actual)
3,719
Serious AEs
0.1%
Results posted
May 2012
Primary outcomePrimary: Percentage of Participants With 7-day Point Prevalence From Week 3 to Less Than Week 7 — 59.55 Percentage of participants

Summary

To monitor use in real practice including safety and efficacy of Champix tablets 0.5mg, 1mg medication for 12 weeks in smokers

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Participants With 7-day Point Prevalence From Week 3 to Less Than Week 7
59.55 —
PRIMARY
Percentage of Participants With 7-day Point Prevalence From Week 7 to Less Than Week 11
73.29 —
PRIMARY
Percentage of Participants With 7-day Point Prevalence for at Least Week 11
77.02 —

Eligibility Criteria

Inclusion Criteria

  • Subjects selected for this study are those who would have been prescribed Champix tablets by the physician according to the subject's condition in usual clinical practice.

Exclusion Criteria

  • None
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00483002). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search